Ceredex Value Advisors Reduces Johnson & Johnson Stock Holdings

Institutional investor cuts stake in pharmaceutical giant by 22.6% in Q3

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Ceredex Value Advisors LLC, an institutional investor, reduced its position in Johnson & Johnson (NYSE: JNJ) by 22.6% in the third quarter, according to a recent 13F filing with the SEC. The firm now owns 238,735 shares of the company's stock, valued at $44,266,000 as of the filing.

Why it matters

Johnson & Johnson is one of the world's largest and most influential pharmaceutical companies, so changes in major institutional holdings can provide insights into investor sentiment and market trends around the stock.

The details

Ceredex Value Advisors sold 69,665 shares of Johnson & Johnson stock during the third quarter, reducing its total position to 238,735 shares. The firm cited unspecified portfolio management decisions as the reason for the reduction in its JNJ holdings.

  • Ceredex Value Advisors filed its 13F report for the third quarter on October 15, 2026.

The players

Ceredex Value Advisors LLC

An institutional investment firm that manages a portfolio of stocks, including a position in pharmaceutical giant Johnson & Johnson.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey. It is one of the most broadly diversified and well-known healthcare companies in the world.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Ceredex's Johnson & Johnson holdings reflects broader trends of institutional investors adjusting their portfolios, though the specific reasons are not entirely clear. As a leading healthcare company, changes in JNJ's shareholder base can provide insights into investor sentiment around the stock and the broader pharmaceutical industry.